抗菌薬感受性検査市場 – 2029年までの世界予測

Report Overview

The global antimicrobial susceptibility testing market is projected to reach USD 5.68 billion by 2029 from USD 4.45 billion in 2024, growing at a CAGR of 5.0% % during the forecast period.

世界の抗菌薬感受性検査市場は、2024年の44億5,000万米ドルから2029年までに56億8,000万米ドルに達すると予測されており、予測期間中に5.0%のCAGRで成長します。

Key advantages of the AST market include the fact that it is very crucial in improving patient care through proper identification and timely selection of effective antimicrobial therapy. AST therefore has an added advantage in combating the rise of the antimicrobial resistance problem in providing correct susceptibility profiles that assist appropriate antibiotic usage.

“Consumables to register largest market share in 2022-2029.”

The largest share in antimicrobial susceptibility testing (AST) is held by the consumables segment. A significant and ever-increasing amount of critical material is consumed. It comprises culture media, reagents, antibiotic discs, and other materials and can be considered basically necessary for AST procedures. The market share of the consumable is thus added to owing to the growing incidence of infectious diseases and the emergence of antibiotic-resistant pathogens and increasing demand for AST services.

Second, the production of more sophisticated AST technologies will need more technical consumables. Obviously, molecular-based AST methods will require specific nucleic acid extraction kits, PCR reagents, and detection probes. Persistent demand for accurate and effective AST testing creates a sustainable demand for consumables, which further solidifies them as the core of the overall AST market.

“Hospitals & diagnostic centers segment held the largest share of antimicrobial susceptibility testing market in 2023, by End-user.”

Based on the end-user, the antimicrobial susceptibility testing market is segmented into hospitals & diagnostic laboratories, pharmaceutical and biotechnology companies, research & academic Institutes and clinical research organizations. In the year 2023, the global antimicrobial susceptibility testing market was dominated by hospitals and diagnostic centers. Growth within the number of hospitals and diagnostic centers in the AST market is also derived from increases in the timely and accurate diagnostics needs for managing infectious diseases and fighting against antimicrobial resistance.

“Asia Pacific to register highest growth rate in the market during the forecast period.”

The Asia Pacific region, and China in particular, is witnessing a very rapid growth in the AST market due to various reasons. The increasing population in this region, allied with increasing incomes and access to better health care, has resulted in more stringent demands for diagnostics services. It is not overstressed in the sense that the ever-growing occurrence of infectious diseases and antimicrobial-resistant pathogens demands utmost importance in attaching real value to accurate AST as the primary basis for guiding proper treatment.

Advances in AST technology, particularly through the development of molecular rapid diagnostics and automated systems, is driving the market.. These speed up the process of AST, give results quicker in turn-around time, have increased efficiency with precise results, which put AST within the reach of healthcare providers. Additionally, the investments done by governments in upgrading the health care infrastructure along with such initiatives have paved a favorable path toward the growth of the market in the country, particularly in China.

A number of drivers were responsible for the upswing, including:

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1–30%, Tier 2–42%, and Tier 3– 28%
• By Designation: C-level– 10%, Director-level–14%, and Others–76%
• By Region: North America–40%, Europe-30%, Asia Pacific–20%, Latin America- 5%, Middle east and africa- 5%

Prominent players in this market are BioMérieux (France), Becton, Dickinson and company (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Bio-Rad laboratories (US), Bruker (US), Roche diagnostics (Switzerland, Accelerate diagnostics (US), Himedia laboratories (India), Liofilchem s.r.l.(Italy), Alifax s.r.l.(Italy), Creative Diagnostics (US),  among others.

Research Coverage

The market is segmented into product, type, method, application, end user, and region. In the report, factors affecting the antimicrobial susceptibility testing market- drivers, restraints, opportunities, and challenges-are described. Opportunities and challenges for stakeholders and the details of leading players’ competitive landscape are also highlighted. The report further segments the micro-markets into growth trends, prospects, and contribution to the antimicrobial susceptibility testing market. It forecasts revenue growth from different market segments, focusing on five major geographical regions.

Key Benefits of Buying the Report:

The report is designed to aid new entrants by providing them with detailed data on the antimicrobial susceptibility testing market, thereby allowing them to understand investment opportunities. It provides comprehensive insight into key players as well as smaller ones, thus favoring strong risk assessment and informed investment decisions. Due to precise segmentation-such as by end-users and regions-the report offers focused insights in specific segments of the market. It further outlines the critical trends, challenges, growth drivers, and opportunities that complete the strategic decision-making process with well-rounded analysis.

The report provides the insights on the following pointers:

Analysis of the key drivers, restraints, opportunities, and challenges influencing the rise of the antimicrobial susceptibility testing market. The key drivers of antimicrobial susceptibility testing are an upsurge in infectious diseases and, correspondingly, higher numbers of antibiotic resistance around the world. Growing demand for timely and accurate diagnostic tools that guide effective treatment strategies fuels demand for AST. Technologically, the development of rapid and automated testing systems supports market growth by increasing efficiency and accuracy in tests.

• Product Development/Innovation: Insights into emerging technologies, current R&D activities, and recent launches of products and services in the antimicrobial susceptibility testing market.
• Market Development: The report further provides in detail the profitable markets by segmenting the antimicrobial susceptibility testing market into various regions
• Market Diversification: Detailed insight into new product launches, unexplored markets, recent developments, and investments made in the antimicrobial susceptibility testing market.
• Competitive Assessment: Detailed assessment of market share, service offerings leading strategies of key players such as BioMérieux (France), Becton, Dickinson and company (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Bio-Rad laboratories (US), among others.

Table of Contents

1               INTRODUCTION              25

1.1           STUDY OBJECTIVES       25

1.2           MARKET DEFINITION   25

1.3           MARKET SCOPE                26

1.3.1        MARKETS COVERED       26

1.3.2        INCLUSIONS AND EXCLUSIONS 27

1.3.3        YEARS CONSIDERED      27

1.3.4        CURRENCY CONSIDERED            27

1.4           STAKEHOLDERS               28

1.5           SUMMARY OF CHANGES               28

2               RESEARCH METHODOLOGY       29

2.1           RESEARCH DATA              29

2.2           RESEARCH DESIGN         30

2.2.1        SECONDARY RESEARCH                30

2.2.2        PRIMARY RESEARCH       32

2.2.2.1    Primary sources    33

2.2.2.2    Key industry insights           34

2.2.2.3    Breakdown of primaries      34

2.3           MARKET SIZE ESTIMATION         35

2.3.1        BOTTOM-UP APPROACH              36

2.3.1.1    Approach 1: Company revenue estimation approach     37

2.3.1.2    Approach 2: Customer-based market estimation             38

2.3.1.3    Approach 3: Top-down approach      39

2.3.1.4    Approach 4: Primary interviews         40

2.3.1.5    CAGR projections                 41

2.4           DATA TRIANGULATION & MARKET BREAKDOWN                 42

2.5           MARKET SHARE ASSESSMENT   43

2.6           STUDY ASSUMPTIONS  43

2.7           ASSUMPTIONS/MARKET FORECASTING METHODOLOGY              43

2.8           LIMITATIONS AND RISK ASSESSMENT   44

3               EXECUTIVE SUMMARY  45

4               PREMIUM INSIGHTS       49

4.1           ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET OVERVIEW          49

4.2           ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY REGION, 2024 VS. 2029 (USD MILLION)             50

4.3           ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY REGION AND END USER, 2023 (USD MILLION)              51

4.4           GEOGRAPHIC GROWTH OPPORTUNITIES IN ANTIMICROBIAL SUSCEPTIBILITY

TESTING MARKET           52

5               MARKET OVERVIEW       53

5.1           INTRODUCTION              53

5.2           MARKET DYNAMICS       54

5.2.1        DRIVERS               54

5.2.1.1    Rising antimicrobial resistance           54

5.2.1.2    Advancements in diagnostic technologies        56

5.2.1.3    Expansion of clinical research applications      57

5.2.1.4    Rise in government initiatives            58

5.2.2        RESTRAINTS      58

5.2.2.1    High cost of automated instruments 58

5.2.3        OPPORTUNITIES              59

5.2.3.1    Emergence of rapid testing solutions                 59

5.2.3.2    Integration with digital health technologies     60

5.2.4        CHALLENGES    61

5.2.4.1    Intricate regulatory landscape            61

5.3           INDUSTRY TRENDS         62

5.3.1        ISOTHERMAL MICROCALORIMETRY       62

5.3.2        FLUORESCENCE-ACTIVATED CELL SORTING     63

5.3.3        SMARTPHONE-BASED OPTICAL SPECTROSCOPY                 63

5.3.4        MICROFLUIDICS AND MICRODROPLETS               63

5.4           ECOSYSTEM ANALYSIS  64

5.5           SUPPLY CHAIN ANALYSIS             65

5.5.1        PROMINENT COMPANIES            65

5.5.2        SMALL AND MEDIUM-SIZED ENTERPRISES          65

5.5.3        END USERS         65

5.6           VALUE CHAIN ANALYSIS               66

5.7           PORTER’S FIVE FORCES ANALYSIS           68

5.7.1        THREAT OF NEW ENTRANTS      69

5.7.2        BARGAINING POWER OF SUPPLIERS       69

5.7.3        BARGAINING POWER OF BUYERS             69

5.7.4        THREAT OF SUBSTITUTES          69

5.7.5        INTENSITY OF COMPETITIVE RIVALRY 69

5.8           KEY STAKEHOLDERS AND BUYING CRITERIA     70

5.8.1        KEY STAKEHOLDERS IN BUYING PROCESS           70

5.8.2        BUYING CRITERIA           71

5.9           PATENT ANALYSIS          72

5.10         TRADE ANALYSIS             75

5.10.1      IMPORT DATA  75

5.10.2      EXPORT DATA  76

5.11         KEY CONFERENCES AND EVENTS, 2024–2025        77

5.12         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       78

5.13         TECHNOLOGY ANALYSIS             78

5.13.1      KEY TECHNOLOGIES     79

5.13.1.1  PCR        79

5.13.1.2  Microfluidics and lab-on-a-chip         79

5.13.1.3  Synthetic antimicrobial peptides        79

5.13.2      COMPLIMENTARY TECHNOLOGIES        79

5.13.2.1  MALDI-TOF        79

5.13.3      ADJACENT TECHNOLOGIES       80

5.13.3.1  Nanotechnology    80

5.13.3.2  Nanomotion technology      80

5.13.3.3  Biochip technology               80

5.14         REGULATORY LANDSCAPE         81

5.14.1      NORTH AMERICA             81

5.14.1.1  US           81

5.14.1.2  Canada   82

5.14.2      EUROPE               82

5.14.3      ASIA PACIFIC     83

5.14.3.1  Japan      83

5.14.3.2  China      84

5.14.3.3  India       84

5.14.4      REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  85

5.15         INVESTMENT AND FUNDING SCENARIO               87

5.16         PRICING ANALYSIS          88

5.16.1      AVERAGE SELLING PRICE, BY REGION   88

5.16.2      AVERAGE SELLING PRICE, BY KEY PLAYER           92

5.17         REIMBURSEMENT SCENARIO     92

5.18         UNMET NEEDS AND KEY PAIN POINTS  94

5.19         IMPACT OF AI/GEN AI ON ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET        94

6               ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT     96

6.1           INTRODUCTION              97

6.2           CONSUMABLES 97

6.2.1        CULTURE & GROWTH MEDIA    98

6.2.1.1    High utilization of disk diffusion and broth dilution methods

to drive market      98

6.2.2        SUSCEPTIBILITY TESTING DISKS              99

6.2.2.1    Low costs, ease of use to support adoption      99

6.2.3        MIC STRIPS         99

6.2.3.1    Accuracy, simplicity, and thorough results to drive usage                 99

6.2.4        SUSCEPTIBILITY TESTING PLATES          100

6.2.4.1    Availability of specialized plates to drive market             100

6.3           LAB INSTRUMENTS         101

6.3.1        AUTOMATED LABORATORY INSTRUMENTS       102

6.3.1.1    Ongoing trend of laboratory automation to fuel segment growth                 102

6.3.2        MOLECULAR DIAGNOSTICS SYSTEMS   103

6.3.2.1    Technological advancements in molecular diagnostics

to propel market   103

6.4           LAB DISPOSABLES           104

6.4.1        INCREASING NUMBER OF SUSCEPTIBILITY TESTS PERFORMED IN HOSPITALS TO DRIVE DEMAND              104

7               ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE               105

7.1           INTRODUCTION              106

7.2           ANTIBACTERIAL SUSCEPTIBILITY TESTING        106

7.2.1        EMERGENCE OF MULTIDRUG-RESISTANCE TO INCREASE ADOPTION OF ANTIBACTERIAL SUSCEPTIBILITY TESTING PRODUCTS     106

7.3           ANTIFUNGAL SUSCEPTIBILITY TESTING              107

7.3.1        INCREASING PREVALENCE OF INFECTIOUS DISEASES TO PROPEL DEMAND FOR TESTING       107

7.4           ANTIPARASITIC SUSCEPTIBILITY TESTING         109

7.4.1        RISING AWARENESS TO SUPPORT MARKET GROWTH                 109

7.5           ANTIVIRAL SUSCEPTIBILITY TESTING   110

7.5.1        ADVANCEMENTS IN ANTIVIRAL SUSCEPTIBILITY TESTING TO ENHANCE PATIENT OUTCOMES   110

8               ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY METHOD      111

8.1           INTRODUCTION              112

8.2           QUALITATIVE METHODS             112

8.2.1        AUTOMATED AST            113

8.2.1.1    Advancements and resistance patterns to drive use of automated instruments            113

8.2.2        DISK DIFFUSION              115

8.2.2.1    Simplicity, accuracy, and flexibility to support adoption                 115

8.2.3        AGAR DILUTION              116

8.2.3.1    Time-consuming and labor-intensive nature to affect adoption                 116

8.2.4        GENOTYPIC METHOD   117

8.2.4.1    Gold standard status to support greater adoption           117

8.3           QUANTITATIVE METHODS         118

8.3.1        ETEST METHOD               119

8.3.1.1    Etest to hold larger share of quantitative methods market                 119

8.3.2        BROTH MACRODILUTION           120

8.3.2.1    Precision, simultaneous testing capability to drive market                 120

9               ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION             121

9.1           INTRODUCTION              122

9.2           CLINICAL DIAGNOSTICS              123

9.2.1        TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET                 123

9.3           DRUG DISCOVERY & DEVELOPMENT     124

9.3.1        EMPHASIS ON R&D AND INNOVATION TO SUPPORT DEMAND GROWTH         124

9.4           EPIDEMIOLOGY               125

9.4.1        NEED FOR BETTER UNDERSTANDING AND DECISION MAKING TO PROPEL ADOPTION              125

9.5           OTHER APPLICATIONS 126

10            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER     127

10.1         INTRODUCTION              128

10.2         HOSPITALS & DIAGNOSTIC CENTERS    128

10.2.1      HOSPITALS & DIAGNOSTIC CENTERS TO HOLD LARGEST MARKET SHARE            128

10.3         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 129

10.3.1      EMPHASIS ON PRODUCT DEVELOPMENT TO DRIVE MARKET               129

10.4         ACADEMIC & RESEARCH INSTITUTES    130

10.4.1      RISING R&D ACTIVITY AND SUPPORT FOR RESEARCH TO DRIVE MARKET         130

10.5         CLINICAL RESEARCH ORGANIZATIONS 132

10.5.1      EXPANSION OF CLINICAL TRIALS WORLDWIDE TO PROPEL MARKET GROWTH         132

11            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION         133

11.1         INTRODUCTION              134

11.2         NORTH AMERICA             135

11.2.1      NORTH AMERICA: MACROECONOMIC OUTLOOK                 135

11.2.2      US           140

11.2.2.1  US to hold largest share of North American market       140

11.2.3      CANADA               142

11.2.3.1  Favorable government initiatives to drive market growth                 142

11.3         EUROPE               144

11.3.1      EUROPE: MACROECONOMIC OUTLOOK               144

11.3.2      GERMANY           149

11.3.2.1  Government initiatives for AMR to drive market            149

11.3.3      FRANCE                150

11.3.3.1  Focus on enhancing AMR surveillance to propel market                 150

11.3.4      UK          152

11.3.4.1  New action plans for AMR to propel adoption                 152

11.3.5      ITALY    153

11.3.5.1  Rising instances of AMR and high use of antibiotics to propel demand for testing                153

11.3.6      SPAIN    155

11.3.6.1  Rising AMR in gram-negative bacilli to drive market     155

11.3.7      REST OF EUROPE             157

11.4         ASIA PACIFIC     158

11.4.1      ASIA PACIFIC: MACROECONOMIC OUTLOOK     159

11.4.2      JAPAN   164

11.4.2.1  Industry-government collaborations for infectious disease management to support market growth            164

11.4.3      CHINA  166

11.4.3.1  Rising emphasis on AMR management to drive market 166

11.4.4      INDIA    168

11.4.4.1  Expanding government and industry efforts in clinical diagnostics to propel market growth      168

11.4.5      AUSTRALIA         170

11.4.5.1  Establishment and implementation of antimicrobial treatment guidelines to favor market growth     170

11.4.6      SOUTH KOREA  172

11.4.6.1  Need for rapid AMR detection to drive demand for automated AST systems          172

11.4.7      REST OF ASIA PACIFIC   173

11.5         LATIN AMERICA                175

11.5.1      LATIN AMERICA: MACROECONOMIC OUTLOOK                 175

11.5.2      BRAZIL 179

11.5.2.1  Rising emphasis on implementing AMR detection to drive market                 179

11.5.3      MEXICO                181

11.5.3.1  Economic growth to support expansion of AST systems                 181

11.5.4      REST OF LATIN AMERICA             182

11.6         MIDDLE EAST & AFRICA                183

11.6.1      MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK                 184

11.6.2      GCC COUNTRIES              188

11.6.2.1  Healthcare infrastructural development initiatives to support growth    188

11.6.3      REST OF MIDDLE EAST & AFRICA             189

12            COMPETITIVE LANDSCAPE         191

12.1         OVERVIEW          191

12.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            191

12.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET     192

12.3         REVENUE ANALYSIS       193

12.4         MARKET SHARE ANALYSIS, 2023                 194

12.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 196

12.5.1      STARS   196

12.5.2      EMERGING LEADERS     196

12.5.3      PERVASIVE PLAYERS      196

12.5.4      PARTICIPANTS 196

12.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2023         198

12.5.5.1  Company footprint               198

12.5.5.2  Region footprint   199

12.5.5.3  Product footprint  200

12.5.5.4  Type footprint       201

12.5.5.5  Method footprint  202

12.5.5.6  Application footprint            203

12.5.5.7  End-user footprint                204

12.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        205

12.6.1      PROGRESSIVE COMPANIES         205

12.6.2      RESPONSIVE COMPANIES            205

12.6.3      DYNAMIC COMPANIES  205

12.6.4      STARTING BLOCKS         205

12.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023                 207

12.7         VALUATION & FINANCIAL METRICS       209

12.7.1      FINANCIAL METRICS      209

12.7.2      COMPANY VALUATION 209

12.8         BRAND/PRODUCT COMPARISON             210

12.9         COMPETITIVE SCENARIO             211

12.9.1      PRODUCT LAUNCHES & APPROVALS     211

12.9.2      DEALS  212

13            COMPANY PROFILES      213

13.1         KEY PLAYERS     213

13.1.1      BIOMÉRIEUX SA                213

13.1.1.1  Business overview 213

13.1.1.2  Products offered   214

13.1.1.3  Recent developments           216

13.1.1.3.1                Product launches & approvals            216

13.1.1.3.2                Deals      217

13.1.1.4  MnM view              217

13.1.1.4.1                Right to win           217

13.1.1.4.2                Strategic choices   217

13.1.1.4.3                Weaknesses & competitive threats     217

13.1.2      BECTON, DICKINSON AND COMPANY   218

13.1.2.1  Business overview 218

13.1.2.2  Products offered   220

13.1.2.3  Recent developments           221

13.1.2.3.1                Deals      221

13.1.2.3.2                Other developments             221

13.1.2.4  MnM view              221

13.1.2.4.1                Right to win           221

13.1.2.4.2                Strategic choices   222

13.1.2.4.3                Weaknesses and competitive threats 222

13.1.3      THERMO FISHER SCIENTIFIC INC.            223

13.1.3.1  Business overview 223

13.1.3.2  Products offered   224

13.1.3.3  Recent developments           226

13.1.3.3.1                Product launches & approvals            226

13.1.3.3.2                Deals      226

13.1.3.4  MnM view              227

13.1.3.4.1                Right to win           227

13.1.3.4.2                Strategic choices   227

13.1.3.4.3                Weaknesses and competitive threats 227

13.1.4      DANAHER CORPORATION           228

13.1.4.1  Business overview 228

13.1.4.2  Products offered   230

13.1.4.3  Recent developments           231

13.1.4.3.1                Product launches & approvals            231

13.1.4.3.2                Deals      232

13.1.4.4  MnM view              233

13.1.4.4.1                Right to win           233

13.1.4.4.2                Strategic choices   233

13.1.4.4.3                Weaknesses and competitive threats 233

13.1.5      BIO-RAD LABORATORIES, INC.  234

13.1.5.1  Business overview 234

13.1.5.2  Products offered   235

13.1.5.2.1                Deals      236

13.1.5.3  MnM view              236

13.1.5.3.1                Right to win           236

13.1.5.3.2                Strategic choices   236

13.1.5.3.3                Weaknesses and competitive threats 236

13.1.6      BRUKER                237

13.1.6.1  Business overview 237

13.1.6.2  Products offered   239

13.1.6.3  Recent developments           241

13.1.6.3.1                Product launches & approvals            241

13.1.6.3.2                Deals      241

13.1.7      ROCHE DIAGNOSTICS   242

13.1.7.1  Business overview 242

13.1.7.2  Products offered   243

13.1.7.3  Recent developments           245

13.1.7.3.1                Product launches & approvals            245

13.1.7.3.2                Deals      246

13.1.8      MERCK KGAA    247

13.1.8.1  Business overview 247

13.1.8.2  Products offered   248

13.1.8.3  Recent developments           249

13.1.8.3.1                Deals      249

13.1.9      ACCELERATE DIAGNOSTICS, INC.            250

13.1.9.1  Business overview 250

13.1.9.2  Products offered   251

13.1.9.3  Recent developments           252

13.1.9.3.1                Product launches & approvals            252

13.1.9.3.2                Deals      252

13.1.9.3.3                Other developments             252

13.1.10   HIMEDIA LABORATORIES            253

13.1.10.1                 Business overview 253

13.1.10.2                 Products offered   254

13.1.11   LIOFILCHEM S.R.L.          255

13.1.11.1                 Business overview 255

13.1.11.2                 Products offered   255

13.1.12   ALIFAX S.R.L.      258

13.1.12.1                 Business overview 258

13.1.12.2                 Products offered   258

13.1.13   CREATIVE DIAGNOSTICS             259

13.1.13.1                 Business overview 259

13.1.13.2                 Products offered   260

13.1.14   SYNBIOSIS          261

13.1.14.1                 Business overview 261

13.1.14.2                 Products offered   262

13.1.15   BIOANALYSE     263

13.1.15.1                 Business overview 263

13.1.15.2                 Products offered   263

13.2         OTHER KEY PLAYERS     264

13.2.1      ZHUHAI DL BIOTECH CO., LTD.                264

13.2.2      ELITECHGROUP               265

13.2.3      MAST GROUP LTD.         267

13.2.4      CONDALAB        268

13.2.5      GENEFLUIDICS, INC.      269

13.2.6      BIOTRON HEALTHCARE               269

13.2.7      INVIVOGEN        270

13.2.8      MP BIOMEDICALS           271

13.2.9      QUANTAMATRIX INC.    271

13.2.10   SYSMEX EUROPE SE        272

13.2.11   COPAN DIAGNOSTICS INC.         272

13.2.12   ERBA DIAGNOSTICS MANNHEIM GMBH                273

14            APPENDIX           274

14.1         DISCUSSION GUIDE        274

14.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                279

14.3         CUSTOMIZATION OPTIONS        281

14.4         RELATED REPORTS         281

14.5         AUTHOR DETAILS           282

LIST OF TABLES

TABLE 1                ANTIMICROBIAL SUSCEPTIBILITY TESTINGMARKET: INCLUSIONS & EXCLUSIONS 27

TABLE 2                LIMITATIONS AND ASSOCIATED RISKS 44

TABLE 3                MITIGATION OF ANTIMICROBIAL RESISTANCE                 55

TABLE 4                COMPARISON OF ANTIMICROBIAL SUSCEPTIBILITY TESTING AUTOMATED

PRODUCT PRICING         59

TABLE 5                DISCREPANCIES BETWEEN FDA-APPROVED AST CRITERIA AND CDC-IDENTIFIED ANTIMICROBIAL RESISTANCE THREATS             61

TABLE 6                ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: ROLE OF COMPANIES

IN ECOSYSTEM 64

TABLE 7                ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: IMPACT OF PORTER’S

FIVE FORCES      68

TABLE 8                INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR

TOP FOUR END USERS (%)          70

TABLE 9                KEY BUYING CRITERIA, BY END USER    71

TABLE 10              LIST OF MAJOR PATENT INNOVATIONS AND PATENT REGISTRATIONS, 2022–2024       73

TABLE 11             IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019–2023 (USD THOUSAND)      75

TABLE 12             EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2019–2023 (USD THOUSAND)      76

TABLE 13              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS                 77

TABLE 14              US FDA: MEDICAL DEVICE CLASSIFICATION                 81

TABLE 15              US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              82

TABLE 16              CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS      82

TABLE 17              JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICALS

AND MEDICAL DEVICES AGENCY             83

TABLE 18              CHINA: CLASSIFICATION OF MEDICAL DEVICES                 84

TABLE 19              NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  85

TABLE 20              EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  85

TABLE 21              ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  86

TABLE 22             LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  86

TABLE 23              REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             87

TABLE 24              AVERAGE SELLING PRICE OF AST PRODUCTS, BY REGION,

2021–2023 (USD THOUSAND)      90

TABLE 25              AVERAGE SELLING PRICE OF TOP 3 APPLICATIONS, BY KEY PLAYER, 2023 (USD)       92

TABLE 26              US: MAJOR CPT CODES ASSOCIATED WITH AST, 2023        93

TABLE 27              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: CURRENT UNMET NEEDS        94

TABLE 28              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               97

TABLE 29              ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         97

TABLE 30              ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY REGION, 2022–2029 (USD MILLION)   98

TABLE 31              CULTURE & GROWTH MEDIA MARKET, BY REGION, 2022–2029 (USD MILLION)          98

TABLE 32              SUSCEPTIBILITY TESTING DISKS MARKET, BY REGION, 2022–2029 (USD MILLION)          99

TABLE 33              MIC STRIPS MARKET, BY REGION, 2022–2029 (USD MILLION) 100

TABLE 34              SUSCEPTIBILITY TESTING PLATES MARKET, BY REGION,

2022–2029 (USD MILLION)            100

TABLE 35              ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         101

TABLE 36              ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET,

BY REGION, 2022–2029 (USD MILLION)   101

TABLE 37              AUTOMATED LABORATORY INSTRUMENTS MARKET,

BY REGION, 2022–2029 (USD MILLION)   103

TABLE 38              MOLECULAR DIAGNOSTICS SYSTEMS MARKET,

BY REGION, 2022–2029 (USD MILLION)   103

TABLE 39              LAB DISPOSABLES MARKET, BY REGION, 2022–2029 (USD MILLION)       104

TABLE 40              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         106

TABLE 41              ANTIBACTERIAL SUSCEPTIBILITY TESTING MARKET,

BY REGION, 2022–2029 (USD MILLION)   107

TABLE 42              US: DEATHS FROM FUNGAL DISEASES, 2021                 108

TABLE 43              ANTIFUNGAL SUSCEPTIBILITY TESTING MARKET,

BY REGION, 2022–2029 (USD MILLION)   108

TABLE 44              ANTIPARASITIC SUSCEPTIBILITY TESTING MARKET,

BY REGION, 2022–2029 (USD MILLION)   109

TABLE 45              ANTIVIRAL SUSCEPTIBILITY TESTING MARKET,

BY REGION, 2022–2029 (USD MILLION)   110

TABLE 46              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY METHOD, 2022–2029 (USD MILLION)                 112

TABLE 47              QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         113

TABLE 48              QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET,

BY REGION, 2022–2029 (USD MILLION)   113

TABLE 49              AVAILABLE AND EMERGING AUTOMATED AST TECHNOLOGIES               114

TABLE 50              AUTOMATED ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY REGION, 2022–2029 (USD MILLION)   115

TABLE 51              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DISK DIFFUSION,

BY REGION, 2022–2029 (USD MILLION)   116

TABLE 52              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR AGAR DILUTION,

BY REGION, 2022–2029 (USD MILLION)   117

TABLE 53              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR GENOTYPIC METHOD,

BY REGION, 2022–2029 (USD MILLION)   118

TABLE 54              QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         118

TABLE 55              QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET,

BY REGION, 2022–2029 (USD MILLION)   119

TABLE 56              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ETEST METHOD,

BY REGION, 2022–2029 (USD MILLION)   120

TABLE 57              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET

FOR BROTH MACRODILUTION, BY REGION, 2022–2029 (USD MILLION)            120

TABLE 58              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)       122

TABLE 59              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2022–2029 (USD MILLION) 123

TABLE 60              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR DRUG DISCOVERY

& DEVELOPMENT, BY REGION, 2022–2029 (USD MILLION)                 124

TABLE 61              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR EPIDEMIOLOGY,

BY REGION, 2022–2029 (USD MILLION)   125

TABLE 62              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR OTHER APPLICATIONS,

BY REGION, 2022–2029 (USD MILLION)   126

TABLE 63              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               128

TABLE 64              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR HOSPITALS &

DIAGNOSTIC CENTERS, BY REGION, 2022–2029 (USD MILLION)                 129

TABLE 65              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)        130

TABLE 66              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)            131

TABLE 67              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET FOR CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)          132

TABLE 68              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY REGION,

2022–2029 (USD MILLION)            134

TABLE 69              NORTH AMERICA: MACROINDICATORS                 135

TABLE 70              NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               137

TABLE 71              NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               137

TABLE 72              NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)            137

TABLE 73              NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)                138

TABLE 74              NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         138

TABLE 75              NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)       138

TABLE 76              NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY METHOD, 2022–2029 (USD MILLION)                 139

TABLE 77              NORTH AMERICA: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION)         139

TABLE 78              NORTH AMERICA: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION)         139

TABLE 79              NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               140

TABLE 80              US: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               141

TABLE 81              US: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         141

TABLE 82              US: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         142

TABLE 83              CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               143

TABLE 84              CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         143

TABLE 85              CANADA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)            143

TABLE 86              EUROPE: MACROINDICATORS   145

TABLE 87              EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               145

TABLE 88              EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               146

TABLE 89              EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         146

TABLE 90              EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)            146

TABLE 91              EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         147

TABLE 92              EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)       147

TABLE 93              EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY METHOD, 2022–2029 (USD MILLION)                 147

TABLE 94              EUROPE: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION)       148

TABLE 95              EUROPE: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION)       148

TABLE 96              EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               148

TABLE 97              GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               149

TABLE 98              GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         149

TABLE 99              GERMANY: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)            150

TABLE 100            FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               151

TABLE 101            FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         151

TABLE 102            FRANCE: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)            151

TABLE 103            UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               152

TABLE 104            UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         153

TABLE 105            UK: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         153

TABLE 106            ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               154

TABLE 107            ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         154

TABLE 108            ITALY: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         155

TABLE 109            SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               156

TABLE 110            SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         156

TABLE 111            SPAIN: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         156

TABLE 112            REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               157

TABLE 113            REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)            158

TABLE 114            REST OF EUROPE: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)                158

TABLE 115            ASIA PACIFIC: MACROINDICATORS         159

TABLE 116            ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               161

TABLE 117            ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               161

TABLE 118            ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)            162

TABLE 119            ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)                162

TABLE 120            ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         162

TABLE 121            ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)       163

TABLE 122            ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY METHOD, 2022–2029 (USD MILLION)                 163

TABLE 123            ASIA PACIFIC: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION)       163

TABLE 124            ASIA PACIFIC: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION)       164

TABLE 125            ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               164

TABLE 126            JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               165

TABLE 127            JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         165

TABLE 128            JAPAN: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         166

TABLE 129            CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               167

TABLE 130            CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         168

TABLE 131            CHINA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         168

TABLE 132            INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               169

TABLE 133            INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         169

TABLE 134            INDIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         170

TABLE 135            AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               171

TABLE 136            AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         171

TABLE 137            AUSTRALIA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)            171

TABLE 138            SOUTH KOREA: LIST OF CONFERENCES ON ANTIMICROBIAL ACTIVITY, 2024               172

TABLE 139            SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               172

TABLE 140            SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)            173

TABLE 141            SOUTH KOREA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)                173

TABLE 142            REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               174

TABLE 143            REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)            174

TABLE 144            REST OF ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)                174

TABLE 145            LATIN AMERICA: MACROINDICATORS  175

TABLE 146            LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               176

TABLE 147            LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               176

TABLE 148            LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)            176

TABLE 149            LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)                177

TABLE 150            LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         177

TABLE 151            LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)       177

TABLE 152            LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY METHOD, 2022–2029 (USD MILLION)                 178

TABLE 153            LATIN AMERICA: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION)         178

TABLE 154            LATIN AMERICA: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION)         178

TABLE 155            LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               179

TABLE 156            BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               180

TABLE 157            BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         180

TABLE 158            BRAZIL: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET,

BY TYPE, 2022–2029 (USD MILLION)         180

TABLE 159            MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               181

TABLE 160            MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         181

TABLE 161            MEXICO: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)            182

TABLE 162            REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               182

TABLE 163            REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)            183

TABLE 164            REST OF LATIN AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)                183

TABLE 165            MIDDLE EAST & AFRICA: MACROINDICATORS                 184

TABLE 166            MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY REGION, 2022–2029 (USD MILLION)   184

TABLE 167            MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               185

TABLE 168            MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)            185

TABLE 169            MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)                185

TABLE 170            MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY TYPE, 2022–2029 (USD MILLION)         186

TABLE 171            MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)       186

TABLE 172            MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY METHOD, 2022–2029 (USD MILLION)                 186

TABLE 173            MIDDLE EAST & AFRICA: QUALITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION)         187

TABLE 174            MIDDLE EAST & AFRICA: QUANTITATIVE ANTIMICROBIAL SUSCEPTIBILITY TESTING METHODS MARKET, BY TYPE, 2022–2029 (USD MILLION)         187

TABLE 175            MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY END USER, 2022–2029 (USD MILLION)               187

TABLE 176            GCC COUNTRIES: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               188

TABLE 177            GCC COUNTRIES: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)            189

TABLE 178            GCC COUNTRIES: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)                189

TABLE 179            REST OF MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT, 2022–2029 (USD MILLION)     190

TABLE 180            REST OF MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING CONSUMABLES MARKET, BY TYPE, 2022–2029 (USD MILLION)     190

TABLE 181            REST OF MIDDLE EAST & AFRICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING LAB INSTRUMENTS MARKET, BY TYPE, 2022–2029 (USD MILLION)     190

TABLE 182            OVERVIEW OF STRATEGIES ADOPTED BY KEY MARKET PLAYERS           192

TABLE 183            ANTIMICROBIAL SUSCEPTIBILITY MARKET: DEGREE OF COMPETITION         194

TABLE 184            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: REGION FOOTPRINT 199

TABLE 185            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: PRODUCT FOOTPRINT             200

TABLE 186            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: TYPE FOOTPRINT       201

TABLE 187            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: METHOD FOOTPRINT               202

TABLE 188            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: APPLICATION FOOTPRINT     203

TABLE 189            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: END-USER FOOTPRINT             204

TABLE 190            ANTIMICROBIAL SUSCEPTIBILITY MARKET: FRANCE DETAILED LIST OF KEY STARTUP/SME PLAYERS                 207

TABLE 191            ANTIMICROBIAL SUSCEPTIBILITY MARKET: COMPETITIVE BENCHMARKING

OF KEY EMERGING PLAYERS/STARTUPS               208

TABLE 192            ANTIMICROBIAL SUSCEPTIBILITY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021– SEPTEMBER 2024              211

TABLE 193            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET:

DEALS, JANUARY 2021– SEPTEMBER 2024               212

TABLE 194            BIOMÉRIEUX: COMPANY OVERVIEW      213

TABLE 195            BIOMÉRIEUX: PRODUCTS OFFERED       214

TABLE 196            BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–SEPTEMBER 2024                216

TABLE 197            BIOMÉRIEUX: DEALS, JANUARY 2021–SEPTEMBER 2024              217

TABLE 198            BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW   218

TABLE 199            BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED    220

TABLE 200            BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021–SEPTEMBER 2024                221

TABLE 201            BECTON, DICKINSON AND COMPANY OTHER DEVELOPMENTS,

JANUARY 2021–SEPTEMBER 2024                221

TABLE 202            THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW          223

TABLE 203            THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED             224

TABLE 204            THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–SEPTEMBER 2024                 226

TABLE 205            THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021–SEPTEMBER 2024   226

TABLE 206            DANAHER CORPORATION: COMPANY OVERVIEW          228

TABLE 207            DANAHER CORPORATION PRODUCTS OFFERED             230

TABLE 208            DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–SEPTEMBER 2024                231

TABLE 209            DANAHER CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024   232

TABLE 210            BIO-RAD LABORATORIES: COMPANY OVERVIEW          234

TABLE 211            BIO-RAD LABORATORIES: PRODUCTS OFFERED                 235

TABLE 212            BIO-RAD LABORATORIES: DEALS, JANUARY 2021–SEPTEMBER 2024   236

TABLE 213            BRUKER: COMPANY OVERVIEW 237

TABLE 214            BRUKER: PRODUCTS OFFERED 239

TABLE 215            BRUKER: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–SEPTEMBER 2024                241

TABLE 216            BRUKER: DEALS, JANUARY 2021–SEPTEMBER 2024        241

TABLE 217            ROCHE DIAGNOSTICS: COMPANY OVERVIEW                 242

TABLE 218            ROCHE DIAGNOSTICS PRODUCTS OFFERED                 243

TABLE 219            ROCHE DIAGNOSTICS: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–SEPTEMBER 2024                245

TABLE 220            ROCHE DIAGNOSTICS: DEALS, JANUARY 2021–SEPTEMBER 2024              246

TABLE 221            MERCK: COMPANY OVERVIEW  247

TABLE 222            MERCK: PRODUCTS OFFERED   248

TABLE 223            MERCK: DEALS, JANUARY 2021–SEPTEMBER 2024                 249

TABLE 224            ACCELERATE DIAGNOSTICS: COMPANY OVERVIEW          250

TABLE 225            ACCELERATE DIAGNOSTICS: PRODUCTS OFFERED             251

TABLE 226            ACCELERATE DIAGNOSTICS: PRODUCT LAUNCHES & APPROVALS,

JANUARY 2021–SEPTEMBER 2024                252

TABLE 227            ACCELERATE DIAGNOSTICS: DEALS, JANUARY 2021–SEPTEMBER 2024   252

TABLE 228            ACCELERATE DIAGNOSTICS: OTHER DEVELOPMENTS,

JANUARY 2021–SEPTEMBER 2024                252

TABLE 229            HIMEDIA LABORATORIES: COMPANY OVERVIEW          253

TABLE 230            HIMEDIA LABORATORIES: PRODUCTS OFFERED             254

TABLE 231            LIOFILCHEM: COMPANY OVERVIEW       255

TABLE 232            LIOFILCHEM: PRODUCTS OFFERED        255

TABLE 233            ALIFAX: COMPANY OVERVIEW  258

TABLE 234            ALIFAX: PRODUCTS OFFERED   258

TABLE 235            CREATIVE DIAGNOSTICS: COMPANY OVERVIEW          259

TABLE 236            CREATIVE DIAGNOSTICS: PRODUCTS OFFERED                 260

TABLE 237            SYNBIOSIS: COMPANY OVERVIEW            261

TABLE 238            SYNBIOSIS: PRODUCTS OFFERED             262

TABLE 239            BIOANALYSE: COMPANY OVERVIEW      263

TABLE 240            BIOANALYSE: PRODUCTS OFFERED       263

LIST OF FIGURES

FIGURE 1              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION           26

FIGURE 2              RESEARCH DESIGN         29

FIGURE 3              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: RESEARCH DESIGN     30

FIGURE 4              KEY DATA FROM SECONDARY SOURCES                 32

FIGURE 5              BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS            34

FIGURE 6              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,

DESIGNATION, AND REGION     35

FIGURE 7              RESEARCH METHODOLOGY: HYPOTHESIS BUILDING           36

FIGURE 8              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE ESTIMATION:

APPROACH 1 (COMPANY REVENUE ESTIMATION)           37

FIGURE 9              ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE ESTIMATION:

BOTTOM-UP APPROACH              38

FIGURE 10            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE ESTIMATION:

END-USER APPROACH  39

FIGURE 11            TOP-DOWN APPROACH                40

FIGURE 12            CAGR PROJECTION: SUPPLY-SIDE ANALYSIS                 41

FIGURE 13            DATA TRIANGULATION METHODOLOGY                 42

FIGURE 14            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY PRODUCT, 2024 VS. 2029 (USD MILLION)        45

FIGURE 15            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY TYPE, 2024 VS. 2029 (USD MILLION)  46

FIGURE 16            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY APPLICATION, 2024 VS. 2029 (USD MILLION) 46

FIGURE 17            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,

BY END USER, 2024 VS. 2029 (USD MILLION)        47

FIGURE 18            GEOGRAPHICAL SNAPSHOT OF ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET     48

FIGURE 19            INCREASING RESEARCH ACTIVITIES AND ADVANCEMENTS IN AUTOMATED & MOLECULAR DIAGNOSTIC INSTRUMENTS TO DRIVE MARKET          49

FIGURE 20            NORTH AMERICAN MARKET TO HOLD LARGEST MARKET SHARE            50

FIGURE 21            HOSPITALS & DIAGNOSTIC CENTERS SEGMENT ACCOUNTED

FOR LARGEST MARKET SHARE IN 2023   51

FIGURE 22            CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD       52

FIGURE 23            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    54

FIGURE 24            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: ECOSYSTEM ANALYSIS              64

FIGURE 25            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: SUPPLY CHAIN ANALYSIS         66

FIGURE 26            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: VALUE CHAIN ANALYSIS           67

FIGURE 27            ANTIMICROBIAL SUSCEPTIBILITY TESTING: PORTER’S FIVE FORCES 68

FIGURE 28            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS     70

FIGURE 29            KEY BUYING CRITERIA, BY END USER    71

FIGURE 30            PATENT ANALYSIS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET (JANUARY 2013–DECEMBER 2023)      72

FIGURE 31            REVENUE SHIFT AND NEW REVENUE POCKETS                 78

FIGURE 32            INVESTMENT AND FUNDING SCENARIO, 2019–2023        87

FIGURE 33            NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023              88

FIGURE 34            VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 (USD MILLION)            88

FIGURE 35            AVERAGE SELLING PRICE OF AST PRODUCTS, BY REGION, 2021–2023 (USD)      90

FIGURE 36            AVERAGE SELLING PRICE FOR TOP 3 APPLICATIONS, BY KEY PLAYER                92

FIGURE 37            NORTH AMERICA: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT                 136

FIGURE 38            ASIA PACIFIC: ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SNAPSHOT                 160

FIGURE 39            CHINA: INCIDENCE OF INFECTIOUS DISEASES, 2023        167

FIGURE 40            REVENUE ANALYSIS OF TOP PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY MARKET, 2019–2023 (USD MILLION)            193

FIGURE 41            MARKET SHARE ANALYSIS OF KEY PLAYERS IN ANTIMICROBIAL SUSCEPTIBILITY MARKET (2023)            194

FIGURE 42            ANTIMICROBIAL SUSCEPTIBILITY MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023       197

FIGURE 43            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY FOOTPRINT             198

FIGURE 44            ANTIMICROBIAL SUSCEPTIBILITY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023                 206

FIGURE 45            EV/EBITDA OF KEY VENDORS   209

FIGURE 46            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA

OF KEY VENDORS            209

FIGURE 47            ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET:

BRAND/PRODUCT COMPARATIVE ANALYSIS     210

FIGURE 48            BIOMÉRIEUX: COMPANY SNAPSHOT (2023)                 214

FIGURE 49            BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT   219

FIGURE 50            THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT          224

FIGURE 51            DANAHER CORPORATION: COMPANY SNAPSHOT          229

FIGURE 52            BIO-RAD LABORATORIES: COMPANY SNAPSHOT          235

FIGURE 53            BRUKER: COMPANY SNAPSHOT                238

FIGURE 54            ROCHE DIAGNOSTICS: COMPANY SNAPSHOT                 243

FIGURE 55            MERCK: COMPANY SNAPSHOT  248

FIGURE 56            ACCELERATE DIAGNOSTICS: COMPANY SNAPSHOT          251

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧